ABC | Volume 113, Nº1, July 2019

Original Article Kızıltunç et al. Sirtuins in acute myocardial infarction patients Arq Bras Cardiol. 2019; 113(1):33-39 Table 1 – Clinical and laboratory characteristics of the study patients Control patients n = 40 AMI patients n = 40 p Value Age, y 59 ± 9 57 ± 14 0.481 Sex, Male, n(%) 23(57.5) 37(92.5) < 0.001 Hypertension, n(%) 20(50) 14(35) 0.175 Smoking, n(%) 8(20) 27(67.5) < 0.001 Diabetes Mellitus, n(%) 16(40) 11(27.5) 0.237 Family History for CAD, n(%) 4(10) 10(25) 0.077 Hyperlipidemia, n(%) 3(7.5) 5(12.5) 0.456 Fasting blood glucose, mmol/L 5.8(5.3-6.7) 5.9(5.4-8.2) 0.164 Creatinine, µmol/L 75 ± 16 84 ± 14 0.006 Total cholesterol, mmol/L 4.9 ± 1.0 4.8 ± 0.9 0.675 HDL, mmol/L 1.1 ± 0.3 1.0 ± 0.2 0.101 LDL, mmol/L 2.7 ± 0.9 2.9 ± 0.8 0.392 Triglyceride, mmol/L 4.3 ± 2.2 3.9 ± 2.2 0.385 Hemoglobin, gr/dl 14.6 ± 1.9 14.7 ± 1.8 0.904 Platelet count, *10 3 279 ± 70 229 ± 52 0.001 WBC, *10 3 8.5 ± 1.9 11.6 ± 3.1 < 0.001 Neutrophil count, *10 3 5.1 ± 1.4 8.8 ± 3.1 < 0.001 Lymphocyte count,*10 3 2.6 ± 0.9 2.0 ± 0.9 0.001 Monocyte count, *10 3 0.8 ± 0.9 0.7 ± 0.3 0.581 CRP, nmol/L 28.5(9.5-57.1) 85.7(38.1-180.9) < 0.001 proBNP,ng/L 48.8(24.2-113.0) 500.9(282.0-1309.0) < 0.001 Sirtuins,ng/ml Sirtuin 1 basal 2.74(2.30-3.64) 2.53(2.06-3.21) 0.192 Sirtuin 1 first day NA 2.24(1.89-2.89) Sirtuin 1 second day NA 2.08(1.55-3.18) Sirtuin 3 basal 2.62(2.16-3.34) 2.40(1.29-3.29) 0.204 Sirtuin 3 first day NA 2.46(1.37-2.97) Sirtuin 3 second day NA 2.30(1.36-3.55) Sirtuin 6 basal 1.13(0.89-2.25) 1.00(0.78-1.37) 0.172 Sirtuin 6 first day NA 1.16(0.87-1.56) Sirtuin 6 second day NA 1.19(0.85-1.80) EF , % 64 ± 2 47 ± 8 < 0.001 LVMI, gr/m 2 87.3 ± 14.6 94.4 ± 16.3 0.044 Continuous variables were presented as mean ± standard deviation or medial (interquartile range 25-75) AMI: acute myocardial infarction; BNP: brain natriuretic peptide; CAD: coronary artery disease; CRP: c reactive protein; EF: ejection fraction; HDL: high density lipoprotein; LDL: low density lipoprotein; LVMI: left ventricle mass index. WBC: white blood cell count. atherosclerosis proceed all over the world. In this context, this study evaluated the implication of serum sirtuin 1, 3 and 6 levels in AMI patients. Preliminary data about the sirtuins in cardiovascular diseases were obtained from experimental studies. It was demonstrated that sirtuin 1 exhibits antiatherogenic properties via acting on endothelium by endothelial nitric oxide synthase activation and reducing macrophage foam cell formation by nuclear factor kB inhibition. 20,21 Another study showed that sirtuin 1 decrease serum LDL cholesterol levels. 22 It was found that sirtuin 1 have antithrombotic effect in addition to the other atheroprotective effects that were mentioned above. 23 Oxidative stress plays an important role in the pathogenesis of atherosclerosis and previous studies reported the antioxidant role of sirtuin 3. 24,25 Sirtuin 6 has anti-inflammatory and LDL lowering features. 26,27 Human data about sirtuins and cardiovascular disorders are limited. Gorenne et al. 28 reported that sirtuin 1 expression is reduced in human carotid atherosclerotic plaque. 28 35